Argos Therapeutics Inc. (NASDAQ:ARGS) fell 4.2% during trading on Monday . The stock traded as low as $4.48 and last traded at $4.51, with a volume of 195,412 shares. The stock had previously closed at $4.71.

A number of equities research analysts have recently issued reports on ARGS shares. Needham & Company LLC restated a “buy” rating on shares of Argos Therapeutics in a research report on Saturday, April 23rd. FBR & Co restated a “buy” rating on shares of Argos Therapeutics in a research report on Saturday, May 14th. Zacks Investment Research upgraded Argos Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a research report on Tuesday, May 17th. Roth Capital upped their price target on Argos Therapeutics from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, April 19th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $11.00 price target on shares of Argos Therapeutics in a research report on Monday, June 20th. Eight investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $11.50.

The company’s 50-day moving average price is $5.68 and its 200-day moving average price is $5.85. The firm’s market cap is $118.34 million.

Argos Therapeutics (NASDAQ:ARGS) last posted its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.05. On average, equities analysts anticipate that Argos Therapeutics Inc. will post ($1.49) EPS for the current fiscal year.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.